【摘要】 目的建立一种针对表皮生长因子受体(EGFR)富集的恶性肿瘤进行靶向基因治疗的方法。方法构建重组真核表达载体pcDNA3.1-PEⅢmut。将组蛋白H1亚基与表皮生长因子C环(H1-EGFc)融合蛋白作为非病毒载体,与pcDNA3.1-PEⅢmut在体外形成复合物。以此蛋白质-DNA复合物分别处理EGFR富集的BT-325和Hela细胞以及EGFR缺乏的JK细胞,并在处理48h后计算该蛋白质-DNA复合物对各细胞的杀伤率。结果含3μgDNA的H1-EGFc与pcDNA3.1-PEⅢmut复合物对EGFR富集的BT-325和Hela细胞的杀伤率分别是46.03%和48.12%,但对EGFR缺乏的JK细胞无杀伤作用。结论成功建立了针对EGFR富集恶性肿瘤的靶向基因治疗方法。更多还原

【Abstract】 Objective To establish a protocol for the targeting gene therapy against cancer with rich epidermal growth factor receptor(EGFR). Methods A recombinant pcDNA3.1-PEⅢmut was constructed and combined with a non-viral vector a fusion protein histone H1 epidermal growth factor C-loop previously expressed by us to be a protein-DNA complex in vitro. Using the complex to treat BT-325 and Hela cancer cells with EGFR and JK cells without EGFR. The killing rates of the cells was calculated after 48 h of incubation at 37℃. Results To BT-325 and Hela cells the killing rates were 46.03% and 48.12% respectively. To JK cells the complex had no killing function. Conclusion The protocol for targeting gene therapy against cancer with EGFR has been established successfully.更多还原